Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen Takes Almost 40% Of US Bevacizumab Market

As Company Launches Biosimilar Infliximab In US

Jul 29 2020

• By Dean Rudge

Large Amgen sign at biopharmaceutical company office in Silicon Valley, biotech company headquartered in Thousand Oaks - South San Francisco, California, USA - 2020 — Amgen has a 32% share of the US trastuzumab market after launching first • Source: Shutterstock

Related Content

Amgen Gets US Infliximab Nod

Dec 09 2019

Updated: Multiple Biosimilars To Avastin Have Launched In EU

Jul 24 2020

Cipla And Amgen Agree To Settle On Sensipar

Jul 28 2020

Nine More Years? Sandoz Loses Again On Enbrel Biosimilar

Jul 02 2020

Amgen Settles On Bevacizumab And Trastuzumab

Jul 08 2020

Related Companies

Amgen, Inc.

Additional Topics

United States International Sales & Earnings Biosimilars Cancer Inflammation BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window